newsfilter
← Latest News
ACCESS Newswire·

Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome

Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon first dosing of first study participant in early 2026 HAMBURG, DE / ACCESS